SNX3-mediated CK-1α PM trafficking rather than proteasomal degradation represents a novel Wnt-independent β-catenin regulatory axis in PF, positioning SNX3 as a promising therapeutic target through dual modulation of β-catenin signaling. This evidence concerns the gene CSNK1A1 and pemphigus foliaceus.